Ozempic Lawsuit Timeline:
2026 Updates
& Settlement Forecast
Ozempic Lawsuit Timeline
Novo Nordisk receives FDA approval for Ozempic (semaglutide) for type 2 diabetes management.
FDA approves Wegovy (higher-dose semaglutide) for chronic weight management, dramatically expanding the patient population.
Early plaintiffs begin filing individual lawsuits alleging gastroparesis and other severe GI injuries caused by Ozempic and Wegovy.
A landmark JAMA study finds GLP-1 users face 9.09× higher risk of gastroparesis, 4.22× higher risk of bowel obstruction, and 3.67× higher risk of pancreatitis compared to non-users.
FDA issues safety communication warning that retained gastric contents in GLP-1 patients pose aspiration risk during anaesthesia and sedation procedures.
The Judicial Panel on Multidistrict Litigation consolidates all federal Ozempic/Wegovy lawsuits into MDL No. 3094 in the Eastern District of Pennsylvania before Judge Gene Pratter.
The MDL court begins the process of selecting bellwether (test) cases to go to trial first, which will set the tone for global settlement negotiations.
Extensive document discovery from Novo Nordisk and Eli Lilly. Internal communications, clinical trial data, and regulatory correspondence are reviewed.
With bellwether trials approaching, settlement negotiations are expected to intensify. Global settlement discussions are anticipated in late 2026 or 2027.
Based on comparable mass tort timelines (Roundup, talc, opioids), a global settlement is anticipated in 2027–2028. Individual payouts are expected to range from $100,000 to $500,000+.
Don't Wait — File Your Claim Now
Cases filed earlier receive priority in settlement distributions. Check your eligibility in 60 seconds. No fees unless you win.
Check My Eligibility